



HAL
open science

A New Composite Model including metabolic syndrome, Alanine aminotransferase and Cytokeratin-18 for the Diagnosis of Non-Alcoholic Steatohepatitis in Morbidly Obese Patients

Rodolphe Anty, Antonio Iannelli, Stéphanie Patouraux, Stephanie Bonnafous,
Vanessa Lavallard, Massimo Senni-Buratti, Imed Ben Amor, Aline
Myx-Staccini, Marie-Christine Saint-Paul, Frédéric Berthier, et al.

► **To cite this version:**

Rodolphe Anty, Antonio Iannelli, Stéphanie Patouraux, Stephanie Bonnafous, Vanessa Lavallard, et al.. A New Composite Model including metabolic syndrome, Alanine aminotransferase and Cytokeratin-18 for the Diagnosis of Non-Alcoholic Steatohepatitis in Morbidly Obese Patients. *Alimentary Pharmacology and Therapeutics*, 2010, 32 (11-12), pp.1315. 10.1111/j.1365-2036.2010.04480.x. hal-00583896

HAL Id: hal-00583896

<https://hal.science/hal-00583896>

Submitted on 7 Apr 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

**A New Composite Model including metabolic syndrome,
Alanine aminotransferase and Cytokeratin-18 for the
Diagnosis of Non-Alcoholic Steatohepatitis in Morbidly
Obese Patients**



Journal:	<i>Alimentary Pharmacology & Therapeutics</i>
Manuscript ID:	APT-0687-2010.R1
Wiley - Manuscript type:	Original Scientific Paper
Date Submitted by the Author:	28-Aug-2010
Complete List of Authors:	<p>Anty, Rodolphe; INSERM U 895, Equipe 8; Hôpital Archet 2, Centre Hospitalier Universitaire de Nice, Pôle Digestif; University of Nice Sophia-Antipolis</p> <p>Iannelli, Antonio; INSERM U 895, Equipe 8; Hôpital Archet 2, Centre Hospitalier Universitaire de Nice, Pôle Digestif; University of Nice Sophia-Antipolis</p> <p>Patouraux, Stéphanie; INSERM U 895, Equipe 8; Hôpital Archet 2, Centre Hospitalier Universitaire de Nice, Pôle Digestif; University of Nice Sophia-Antipolis</p> <p>Bonnafeous, Stéphanie; INSERM U 895, Equipe 8; Hôpital Archet 2, Centre Hospitalier Universitaire de Nice, Pôle Digestif; University of Nice Sophia-Antipolis</p> <p>Lavallard, Vanessa; INSERM U895, Equipe 8; University of Nice-Sophia Antipolis</p> <p>Senni-Buratti, Massimo; Hôpital Archet 2, Centre Hospitalier Universitaire de Nice, Pôle Digestif</p> <p>Ben Amor, Imed; Hôpital Archet 2, Centre Hospitalier Universitaire de Nice, Pôle Digestif</p> <p>Myx-Staccini, Aline; Hôpital Archet 2, Centre Hospitalier Universitaire de Nice, Pôle Digestif</p> <p>Saint-Paul, Marie-Christine; Hôpital Archet 2, Centre Hospitalier Universitaire de Nice, Pôle Digestif</p> <p>Berthier, Frédéric; Hôpital Princesse Grace, Service d'information Médicale</p> <p>Huet, Pierre-Michel; Hôpital Archet 2, Centre Hospitalier Universitaire de Nice, Pôle Digestif</p> <p>Le Marchand-Brustel, Yannick; Hôpital Archet 2, Centre Hospitalier Universitaire de Nice, Pôle Digestif; INSERM U 895, Equipe 8; University of Nice-Sophia Antipolis</p> <p>Gugenheim, Jean; Hôpital Archet 2, Centre Hospitalier Universitaire de Nice, Pôle Digestif; INSERM U 895, Equipe 8; University of Nice-Sophia Antipolis</p> <p>Gual, Philippe; Hôpital Archet 2, Centre Hospitalier Universitaire de Nice, Pôle Digestif; INSERM U 895, Equipe 8; University of Nice-</p>

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Sophia Antipolis Tran, Albert; Hôpital Archet 2, Centre Hospitalier Universitaire de Nice, Pôle Digestif; INSERM U 895, Equipe 8; University of Nice-Sophia Antipolis
Keywords:	Non-alcoholic fatty liver disease < Hepatology, Steatohepatitis < Hepatology, Obesity < Topics, Symptom score or index < Topics

SCHOLARONE™
Manuscripts

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

A New Composite Model including metabolic syndrome, Alanine aminotransferase and Cytokeratin-18 for the Diagnosis of Non-Alcoholic Steatohepatitis in Morbidly Obese Patients

Rodolphe Anty^{1,2,3}, Antonio Iannelli^{1,2,3}, Stéphanie Patouraux^{1,2,4}, Stéphanie Bonnafous^{1,2,3}, Vanessa Lavallard^{1,2,3}, Massimo Senni-Buratti², Imed Ben Amor², Aline Staccini-Myx², Marie-Christine Saint-Paul^{1,4}, Frédéric Berthier⁵, Pierre-Michel Huet², Yannick Le Marchand-Brustel^{1,2,3}, Jean Gugenheim^{1,2,3}, Philippe Gual^{1,2,3}, Albert Tran^{1,2,3}

¹Institut National de la Santé et de la Recherche Médicale (INSERM), U895, Team 8, “Hepatic Complications in Obesity”, Nice, F-06204, Cedex 3, France

²Centre Hospitalier Universitaire of Nice, Digestive Center, Nice, F-06202, Cedex 3, France

³University of Nice-Sophia-Antipolis, Faculty of Medecine, Nice, F-06107, Cedex 2, France

⁴Centre Hospitalier Universitaire of Nice, Biological Center, Nice, F-06107, Nice, Cedex 2, France

⁵Centre Hospitalier Princesse Grace, Medical Information Department, Monaco, MC 98012, Monaco.

Correspondance :

Dr Rodolphe ANTY, Centre Hospitalier Universitaire of Nice, Pôle Référence Hépatite C, Hôpital de l’Archet 2, 151, Route Saint-Antoine de Ginestière. BP 3079, F, 06202 Nice, Cedex 3, France.

Mail: anty.r@chu-nice.fr, Phone: (33) 04 92 03 59 43 (from outside of France, don’t dial the 0),

Mobile Phone: (33) 06 67 48 53 65 (from outside of France, don’t dial the 0)

Abbreviated title: A model to diagnose NASH in morbid obesity

Keywords: fatty liver, Alanine Aminotransferase, Metabolic syndrome, Cytokeratin-18 fragment levels, scoring system

Word count (main text without references): 2622; References: 34; Figure: 2; Tables: 6

ABSTRACT (200 words)

Background and aims: Non invasive approaches are useful to differentiate simple steatosis from non-alcoholic steatohepatitis (NASH) in obese and morbidly obese patients. The aim of this study was to develop a new scoring system to diagnose definitive NASH.

Methods: Preoperative clinical and biological data including serum caspase 3-generated cytokeratin-18 fragments (CK18) and peroperative liver biopsies were obtained from 464 morbidly obese patients who had undergone bariatric surgery. The cohort was divided into two groups: training group (n=310) and validation group (n=154). Definitive NASH was defined according to Kleiner's classification with a NAFLD Activity Score (NAS) ≥ 5 .

Results: Alanine aminotransferase (ALT), CK18 fragments and the presence of metabolic syndrome (MS) were independent predictors for discriminating patients with NAS ≥ 5 in the training group. These three parameters were used to carry out a scoring system for the prediction of NAS ≥ 5 . Whereas serum CK18 fragment alone had an Area under the Receiver Operating Characteristic (AUROC) curve = 0.74, AUROC curves of the scoring system were 0.88 and 0.83 in the training and in the validation group respectively.

Conclusion: A simple and non invasive composite model including MS, ALT and CK18 fragments was able to accurately predict NAS ≥ 5 in morbidly obese subjects.

MAIN TEXT

Non-alcoholic fatty liver disease (NAFLD) is a spectrum of pathological liver abnormalities ranging from pure steatosis to non-alcoholic steatohepatitis (NASH), and finally to severe fibrosis and cirrhosis.¹ Classically, pure steatosis has a relatively good prognosis whereas steatohepatitis is associated with progression of liver fibrosis.^{2, 3} Thus, differentiation of these two states is important. NAFLD is common in the context of morbid obesity and NASH can be present in 20–40% of these patients.^{4, 5}

The mechanisms of NAFLD development are complex and poorly understood. Chronic low grade chronic inflammation, adipokines dysregulation and insulin resistance in the liver and visceral adipose tissue are the major contributing factors.^{6, 7} NAFLD has been considered as the hepatic manifestation of so-called “metabolic syndrome”(MS), a syndrome highly related to morbid obesity with its well defined components: increased waist circumference, high blood pressure, high blood triglycerides, low blood high-density lipoprotein (HDL) cholesterol, and high blood glucose level.^{5, 8-10} Hepatocyte apoptosis may also play an important role in the liver injury and disease progression in NAFLD.¹¹

Liver biopsy is still considered the gold standard to assess hepatic pathology in most chronic liver diseases, including NAFLD, but it is an invasive technique. Moreover, liver biopsy is associated with sampling and inter-observer variability, which might explain the differences in prevalence of NASH in morbidly obese patients reported in previous studies.^{4, 12, 13} In addition, the large number of patients with morbid obesity exposed to NAFLD renders systematic liver biopsy in all patients difficult. The availability of a non-invasive test would allow systematic diagnosis in this particularly predisposed subpopulation and would enable repeated assessment during the follow-up in a more feasible way than liver biopsy. Unfortunately, medical imaging techniques (ultrasound, computerized tomography and magnetic resonance imaging) fail to differentiate pure steatosis from NASH.¹⁴ Moreover, echography in severely or morbidly obese patients is frequently of poor quality.

Several non-invasive scoring models using routine clinico-biological parameters have been proposed for the diagnosis of NASH, but most of them have not been thoroughly validated.¹⁵⁻¹⁹

Recently, apoptotic caspase-3 generated cytokeratin 18 (CK18) fragments in the blood were reported to predict histological NASH in cohorts of obese patients or in patients with insulin resistance.²⁰⁻²³

1
2
3 The aim of this study was to develop a scoring system to diagnose **definitive** NASH using clinical and
4
5 biological data related to the metabolic syndrome and liver injury including caspase-3 generated CK18
6
7 fragment, in a large cohort of European morbidly obese patients.
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Patients and Methods

Study population

Four-hundred and sixty four consecutive morbidly obese patients, referred for bariatric surgery, were included between January 2003 and April 2009. A division of the initial cohort in 2 groups was carried out in order to be able to have a training and a validation patient cohort. The patients were arbitrarily divided into two groups: (i) a training patient cohort consisting of 310 patients (43 men, 267 women, mean age 40.0 ± 10.7 years) enrolled from January 2003 to April 2007; and (ii) a validation patient cohort consisting of 154 patients enrolled from May 2007 to April 2009.

The study protocol was performed according to French legislation regarding Ethic and Human Research and was approved by the local Ethics Committee (Huriet-Serusclet law, DGS 2003/0395). Written informed consent was obtained from all patients. All patients met the 1991 NIH Consensus Conference guidelines for gastrointestinal surgery for obesity.²⁴ All patients were negative for hepatitis B and C viral markers, autoantibodies indicative of autoimmune hepatitis, and had negligible alcohol consumption (<20 g/day). Alcohol abuse was also excluded by interviewing the patients' relatives. Patients with a history of inflammatory disease (including rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease), current infections, recent history of cancer (<5 years), and severe pulmonary or cardiac disease were not enrolled in the study. All patients underwent a Roux-en-Y divided gastric bypass and a surgical liver biopsy was obtained during surgery.

Preoperative assessment

Preoperative assessment included: history and physical examination; blood pressure determination; anthropometric investigations (weight, height, waist circumference); psychiatric and nutritional evaluation; blood samples were also obtained before surgery after overnight fasting for the determination of plasma levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ glutamyl transferase (γ GT), glucose, insulin, C-peptide, glycosylated hemoglobin, triglycerides, HDL cholesterol, low density lipoprotein (LDL) cholesterol, ferritin. ALT and AST levels were determined using the Roche® assay with pyridoxal phosphate on a Hitachi Modular® according to the International Federation of Clinical Chemistry and the Société Française de Biologie

1
2
3 Clinique recommendations. Glycosylated hemoglobin was obtained with the Dual kit A1c Biorad® on
4
5 a Variant 2 Biorad® (Biorad, USA). Blood levels of apoptotic caspase-3 generated CK18 fragment
6
7 levels were measured using ELISA kit M30-Apoptosense® (Peviva, Bromma, Sweden) according to
8
9 the manufacturer's instructions. All patients also had a chest X ray, electrocardiogram, abdominal
10
11 ultrasound and upper gastrointestinal endoscopy.

12
13 Insulin resistance was assessed by homeostasis model assessment of insulin resistance (HOMA-IR).
14
15 HOMA-IR is the product of fasting plasma insulin concentration (mIU/L) and glucose
16
17 concentration (mmol/L) divided by 22.5.²⁵

18
19 MS was diagnosed according to the International Diabetes Federation (IDF) as follows: central
20
21 obesity defined by a increased waist circumference (≥ 80 cm in women and ≥ 94 cm in men) and any
22
23 two of the following criteria: (i) triglycerides ≥ 1.7 mmol/L or treatment for hypertriglyceridemia; (ii)
24
25 HDL-cholesterol < 1.29 mmol/L in women and < 1.03 mmol/L in men; (iii) systolic blood pressure (BP)
26
27 ≥ 130 mmHg or diastolic BP ≥ 85 mmHg or treatment for hypertension; and (iv) fasting plasma glucose
28
29 ≥ 5.6 mmol/L or previously diagnosed type-2 diabetes. (8) All the morbid obese patients of this study
30
31 had a rise in the waist circumference. Type-2 diabetes was defined by two measurements of elevated
32
33 fasting plasma glucose ≥ 7 mmol/L.

34 35 36 37 *Pathological liver assessment*

38
39 **Hepatic wedges were obtained during bariatric surgery.** Surgical liver biopsies were reviewed by two
40
41 liver pathologists (MC-SP and SP) without knowledge of the clinical or biological characteristics of
42
43 the patients. Routine haematoxylin-eosin-safran and sirius red staining were performed on all
44
45 biopsies. All biopsies were graded according to the NAFLD Activity Score (NAS). This score
46
47 classifies patients as simple steatosis ($NAS \leq 2$), borderline group ($3 \leq NAS \leq 4$) or definitive NASH
48
49 ($NAS \geq 5$).²⁶ Patients were analyzed as with or without $NAS \geq 5$.

50
51
52 Liver bridging fibrosis was assessed by sirius red staining and was classified into five stages as
53
54 follows: absent, mild, moderate (incomplete septa), severe (with complete septa) and cirrhosis.

55 56 57 *Statistical analysis*

58
59 Statistical analysis was first performed on the training patient cohort (n=310) in three steps: (i)
60
univariate analysis of clinical and biochemical parameters was carried out for patients with $NAS < 5$ and

1
2
3 NAS ≥ 5 . The most relevant parameters for classifying the patients were noted. Continuous data are
4 described as means \pm standard deviation (SD). Comparisons were done using the Chi^2 test or Fischer's
5 exact tests for nominal data and by two-sample t tests for continuous data; (ii) multivariate analyses were
6 performed using binary logistic regression with estimation of odds ratios (OR) and 95% confidence
7 intervals (95%CI). The most statistically significant (with $p < 0.05$) and clinically relevant variables in the
8 univariate step were included in a multivariate model, and only variables with $p < 0.05$ were retained for
9 the final model; (iii) the final model was determined by logistic regression to predict NAS ≥ 5 and based
10 on three parameters: CK18 fragment levels, ALT and MS. The diagnostic performance of this model
11 was determined by constructing a receiver-operating characteristic (ROC) curve and calculating the area
12 under ROC (AUROC) curve for predicting patients with NAS ≥ 5 . From this curve, the best cut-off value
13 was established for the model score; this value maximized the sum of the sensitivity and specificity to
14 identify patient status. The diagnostic accuracy of the logarithmic transformation of the *Nice Model*
15 $(\text{Prob}(Y < > \text{group}) = 1/(1 + \text{Exp}(-\text{Nice Model}))$ was then determined. Sensitivity, specificity, positive
16 predictive value, negative predictive value and likelihood ratio were determined for each cutoff value
17 of the *Nice Model*.

18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36 Statistical analysis was then carried out on the validation patient cohort ($n=154$). The main parameters of
37 both cohorts were compared using Chi^2 test or Fischer's exact tests for nominal data, and by two-sample
38 t tests for continuous data. The final model obtained in the training patient cohort was applied to the
39 validation patient cohort. The diagnostic performance of the model was determined by constructing a
40 ROC curve and calculating the AUROC curve for prediction of patients with NAS ≥ 5 .

41
42
43
44
45
46 All statistical analyses were performed using NCSS 2007 software.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Results

Pathological findings and univariate analysis

The distribution of NAS scores among the 310 patients in the training patient cohort is shown in the table 1. Using Kleiner's classification, 39 patients had $NAS \geq 5$. Fibrosis reported using bridging fibrosis grade was absent in 13 patients, mild perivenular and/or periportal fibrosis in 281, septal fibrosis in 15 patients and severe fibrosis in one patient.

Using the univariate analysis (Table 2), patients with $NAS \geq 5$ had higher waist circumference, ALT, γ GT, triglyceride levels, blood glucose levels, C peptide, glycosylated hemoglobin, HOMA-IR, ferritin and CK18 fragment levels compared to patients with $NAS < 5$. HDL-cholesterol was lower in the more severe patients. Rates of type 2 diabetes mellitus and MS were also higher in patients with $NAS \geq 5$ (Table 2). Neither age nor body mass index (BMI) were associated with $NAS \geq 5$.

Multivariate analysis

Multivariate analysis included a model combining ALT, γ GT, HOMA-IR, CK18 fragment levels, gender and MS in the training patient cohort. ALT (OR=1.04 [95%CI: 1.01-1.07], $p=0.002$), MS (OR=7.3, [95%CI: 1.8-29.4], $p=0.005$) and CK18 fragments (OR=1.003, [95%CI: 1.0006-1.005], $p=0.044$) were the only independent variables when $NAS \geq 5$ was the judgment criterion (Table 3).

CK18 fragments, ALT and IDF metabolic syndrome for the prediction of $NAS \geq 5$

AUROC curves for CK18 fragments, ALT and MS were assessed for the prediction of liver disease ($NAS \geq 5$) in the training patient cohort. The AUROC curves were 0.74, 0.78 and 0.74 for the CK18 fragment levels, ALT and MS respectively for the prediction of $NAS \geq 5$.

Model to predict $NAS \geq 5$ in morbidly obese patients

A new model combining these three values was constructed by logistic regression in the training patient cohort, the "Nice Model". The equation of this model was: $-5.654 + 3.780E-02 * ALT \text{ (IU/L)} + 2.215E-03 * CK18 \text{ fragment levels (IU/L)} + 1.825 * (\text{Presence of MS}=1)$. The AUROC curve for the prediction of $NAS \geq 5$ was 0.88 (Figure 1). The diagnostic accuracy of the logarithmic transformation

1
2
3 of the *Nice Model* ($\text{Prob}(Y \leq \text{group}) = 1/(1 + \text{Exp}(-\text{Nice Model}))$) is shown in Table 4. The best cutoff
4
5 value was 0.14. This value was associated with a sensitivity of 0.84, a specificity of 0.86, a positive
6
7 predictive value of 0.44 and negative predictive value of 0.98. The prevalence of $\text{NAS} \geq 5$ was 0.12.

8
9
10 The distribution of values from the *Nice Model* according to liver histology in the training patient
11
12 cohort is shown in Figure 2. Box plots were constructed either separating patients into simple steatosis
13
14 ($\text{NAS} \leq 2$), borderline group ($3 \leq \text{NAS} \leq 4$) or definitive NASH (Figure 2A) or between $\text{NAS} \geq 5$ and NAS
15
16 < 5 (Figure 2B). *Nice Model* values were significantly higher in patients with $\text{NAS} \geq 5$ compared to
17
18 borderline ($p < 0.00001$) and to simple steatosis groups ($p < 0.00001$). *Nice Model* values in the
19
20 borderline group were also significantly higher than in the simple steatosis group ($p < 0.00001$). In the
21
22 same way, patients with $\text{NAS} \geq 5$ had significantly higher *Nice Model* values compared to patients with
23
24 $\text{NAS} < 5$ ($P < 0.0001$).

25 26 27 28 29 *Evaluation of the Nice Model in the validation cohort of morbidly obese patients*

30
31 The training patient and validation patient cohort were similar in terms of age, gender, BMI, ALT,
32
33 CK18 fragment levels, prevalence of MS, as shown in Table 5. The number of patients with $\text{NAS} \geq 5$
34
35 was also similar in the two cohorts (12.6% versus 9%, $P = \text{NS}$). AUROC curves for the prediction of
36
37 $\text{NAS} \geq 5$ was 0.83 (Figure 1).

38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Discussion

We propose a new composite scoring system (*Nice Model*) based on ALT, CK18 fragment levels and the presence of MS to diagnose $NAS \geq 5$ in morbidly obese patients. Indeed, the ALT, CK18 fragment levels or presence of MS separately were moderately predictive of $NAS \geq 5$. The association of these three items in the *Nice Model* displayed an AUROC for $NAS \geq 5$ of 0.88 and 0.83 in the training (n=310) and in the validation (n=154) cohort of morbidly obese patients respectively.

Assessment of CK18 fragment levels has recently been proposed as a marker for NASH in patients exposed to NAFLD. The value of this marker was suggested by a pilot study and was confirmed in a large multicentre study in obese patients.^{20, 27} The disadvantage of the assessment of CK18 fragment levels is that it is not performed routinely in daily practice, but it has the advantage that it is a commercial ELISA kit. The CK18 fragment levels have also been studied in morbidly obese patients. In a cohort of 99 morbidly obese patients, CK18 fragment levels were found to be associated with NASH. CK18 fragment levels AUROC curve was 0.88.²¹ This value was higher than the one found in our training patient group (AUROC curve value only of 0.74) to predict $NAS \geq 5$. Difference in the diagnostic accuracy could be due to the influence of fibrosis on the CK18 fragments levels. As reported by the previous authors CK18 fragments levels were significantly higher in subjects with moderate to severe fibrosis versus those with no or mild fibrosis.²¹

In order to improve the prediction of **definitive** NASH, we attempted to develop a new scoring system combining variables significantly associated with $NAS \geq 5$ in univariate and multivariate analysis. These variables were CK18 fragment levels, ALT and the presence of metabolic syndrome. ALT level has previously been related to inflammatory liver damage during NASH in morbidly obese patients and to an elevated risk of appearance of MS, diabetes and cardiovascular events.^{17, 28} However, ALT alone would not be sufficient for predicting NASH because it has been reported normal levels of transaminases in patients with proven steatohepatitis and/or significant or severe fibrosis due to NASH.²⁹⁻³¹

Presence of Metabolic syndrome in our model is not surprising because it is strongly associated with liver complications. However, in our cohort, metabolic syndrome alone is poorly predictive of **definitive** NASH.

1
2
3 Our scoring system offers the original association of CK18 fragment levels, ALT and MS to diagnose
4 **definitive** NASH. Several non-invasive tests have been proposed for the diagnosis of NASH. Among
5
6 the different models proposed,^{16, 19, 22, 33, 34} we evaluated only those with items available in our
7
8 cohort.^{15, 17, 18} **Respective AUROC of these models applied in the entire cohort (n=464) are**
9
10 **summarized in table 6.**

11
12 One of the weaknesses of this study is that our model is developed among morbidly obese patients.
13
14 The clinical utility of this model will be fully acquired only when a validation on overweight and
15
16 simple obese patients will have been carried out. **Another point is the relatively small number of**
17
18 **patients with NAS \geq 5 which could limit the statistical power of analyses.**

19
20 **Pure steatosis had classically a relatively good prognosis whereas steatohepatitis was associated with**
21
22 **liver fibrosis. However, it was recently suggested that patients with low NAS could develop NASH**
23
24 **and fibrosis progression.³² Even if patients with definitive NASH could have a more severe prognosis,**
25
26 **clinicians should keep in mind that all patients with NAFLD should undergo periodic assessment and**
27
28 **treatment.**

29
30 In conclusion, a new composite model, the *Nice Model*, for the diagnosis of definitive NASH in
31
32 morbidly obese patients based on ALT and CK18 fragment levels and on the presence of a MS is
33
34 proposed. The diagnostic accuracy of this model was better than using CK18 fragment levels, ALT
35
36 and the presence of a MS alone. Possibility of the *Nice Model* to be an alternative to liver biopsy in the
37
38 follow up of obese patients and in the evaluation of treatments aimed at preventing the progression of
39
40 liver disease in these high risks patients should be assessed. The identification of non invasive scoring
41
42 system independent of the severity of obesity and the ethnicity constitute an important challenge for
43
44 the diagnosis of NASH.
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. *Gastroenterology* 2008; **134**(6): 1682-98.
2. Ekstedt M, Franzen LE, Mathiesen UL, *et al.* Long-term follow-up of patients with NAFLD and elevated liver enzymes. *Hepatology* 2006; **44**(4): 865-73.
3. Adams LA, Lymp JF, St Sauver J, *et al.* The natural history of nonalcoholic fatty liver disease: a population-based cohort study. *Gastroenterology* 2005; **129**(1): 113-21.
4. Machado M, Marques-Vidal P, Cortez-Pinto H. Hepatic histology in obese patients undergoing bariatric surgery. *J Hepatol* 2006; **45**(4): 600-6.
5. Huang HL, Lin WY, Lee LT, Wang HH, Lee WJ, Huang KC. Metabolic syndrome is related to nonalcoholic steatohepatitis in severely obese subjects. *Obes Surg* 2007; **17**(11): 1457-63.
6. Maher JJ, Leon P, Ryan JC. Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis. *Hepatology* 2008; **48**(2): 670-8.
7. Greenfield V, Cheung O, Sanyal AJ. Recent advances in nonalcoholic fatty liver disease. *Curr Opin Gastroenterol* 2008; **24**(3): 320-7.
8. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation. *Diabet Med* 2006; **23**(5): 469-80.
9. Lee WJ, Huang MT, Wang W, Lin CM, Chen TC, Lai IR. Effects of obesity surgery on the metabolic syndrome. *Arch Surg* 2004; **139**(10): 1088-92.
10. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. *Nature* 2006; **444**(7121): 881-7.
11. Feldstein AE, Canbay A, Angulo P, *et al.* Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. *Gastroenterology* 2003; **125**(2):

1
2
3 437-43.
4

5 12. Ratziu V, Charlotte F, Heurtier A, *et al.* Sampling variability of liver biopsy in
6 nonalcoholic fatty liver disease. *Gastroenterology*. 2005; **128**(7): 1898-906.
7

8 13. Merriman RB, Ferrell LD, Patti MG, *et al.* Correlation of paired liver biopsies in
9 morbidly obese patients with suspected nonalcoholic fatty liver disease. *Hepatology* 2006;
10 **44**(4): 874-80.
11

12 14. Saadeh S, Younossi ZM, Remer EM, *et al.* The utility of radiological imaging in
13 nonalcoholic fatty liver disease. *Gastroenterology* 2002; **123**(3): 745-50.
14

15 15. Palekar NA, Naus R, Larson SP, Ward J, Harrison SA. Clinical model for
16 distinguishing nonalcoholic steatohepatitis from simple steatosis in patients with nonalcoholic
17 fatty liver disease. *Liver Int* 2006; **26**(2): 151-6.
18

19 16. Campos GM, Bambha K, Vittinghoff E, *et al.* A clinical scoring system for predicting
20 nonalcoholic steatohepatitis in morbidly obese patients. *Hepatology* 2008; **47**(6): 1916-23.
21

22 17. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of
23 nonalcoholic steatohepatitis and liver fibrosis in the severely obese. *Gastroenterology* 2001;
24 **121**(1): 91-100.
25

26 18. Gholam PM, Flancbaum L, Machan JT, Charney DA, Kotler DP. Nonalcoholic fatty
27 liver disease in severely obese subjects. *Am J Gastroenterol* 2007; **102**(2): 399-408.
28

29 19. Poynard T, Ratziu V, Charlotte F, *et al.* Diagnostic value of biochemical markers
30 (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic
31 fatty liver disease. *BMC Gastroenterol* 2006;6: 34.
32

33 20. Feldstein AE, Wieckowska A, Lopez AR, Liu YC, Zein NN, McCullough AJ.
34 Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a
35 multicenter validation study. *Hepatology* 2009; **50**(4): 1072-8.
36

37 21. Diab DL, Yerian L, Schauer P, *et al.* Cytokeratin 18 fragment levels as a noninvasive
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 biomarker for nonalcoholic steatohepatitis in bariatric surgery patients. Clin Gastroenterol
4
5 Hepatol 2008; **6**(11): 1249-54.

6
7
8 22. Younossi ZM, Jarrar M, Nugent C, et al. A novel diagnostic biomarker panel for
9
10 obesity-related nonalcoholic steatohepatitis (NASH). Obes Surg 2008; **18**(11): 1430-7.

11
12
13 23. Yilmaz Y. Systematic review: caspase-cleaved fragments of cytokeratin 18 - the
14
15 promises and challenges of a biomarker for chronic liver disease. Aliment Pharmacol Ther
16
17 2009; **30**(11-12): 1103-9.

18
19
20 24. NIH conference. Gastrointestinal surgery for severe obesity. Consensus Development
21
22 Conference Panel. Ann Intern Med 1991; **115**(12): 956-61.

23
24
25 25. Wallace T, Matthews D. The assessment of insulin resistance in man. Diabet Med
26
27 2002; **19**: 527-534.

28
29
30 26. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological
31
32 scoring system for nonalcoholic fatty liver disease. Hepatology 2005; **41**(6): 1313-21.

33
34
35 27. Wieckowska A, Zein NN, Yerian LM, Lopez AR, McCullough AJ, Feldstein AE. In
36
37 vivo assessment of liver cell apoptosis as a novel biomarker of disease severity in
38
39 nonalcoholic fatty liver disease. Hepatology 2006; **44**(1): 27-33.

40
41
42 28. Goessling W, Massaro JM, Vasan RS, D'Agostino RB, Sr., Ellison RC, Fox CS.
43
44 Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular
45
46 disease. Gastroenterology 2008; **135**(6): 1935-44.

47
48
49 29. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of
50
51 nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; **37**(6):
52
53 1286-92.

54
55
56 30. Kunde SS, Lazenby AJ, Clements RH, Abrams GA. Spectrum of NAFLD and
57
58 diagnostic implications of the proposed new normal range for serum ALT in obese women.
59
60 Hepatology 2005; **42**(3): 650-6.

- 1
2
3 31. Fracanzani AL, Valenti L, Bugianesi E, *et al.* Risk of severe liver disease in
4 nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin
5 resistance and diabetes. *Hepatology* 2008; **48**(3): 792-8.
6
7
8
9
10 32. Wong VW, Wong GL, Choi PC, *et al.* Disease progression of non-alcoholic fatty liver
11 disease: a prospective study with paired liver biopsies at 3 years. *Gut* 2010; **59**(7): 969-74.
12
13
14
15 33. Ulitsky A, Ananthakrishnan AN, Komorowski R, *et al.* A Noninvasive Clinical
16 Scoring Model Predicts Risk of Nonalcoholic Steatohepatitis in Morbidly Obese Patients.
17 *Obes Surg* 2010: 25.
18
19
20
21
22 34. Munteanu M, Ratziu V, Morra R, Messous D, Imbert-Bismut F, Poynard T.
23 Noninvasive biomarkers for the screening of fibrosis, steatosis and steatohepatitis in patients
24 with metabolic risk factors: FibroTest-FibroMax experience. *J Gastrointestin Liver Dis* 2008;
25
26
27
28
29 **17**(2): 187-91.
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

FUNDING:

This work was supported by grants from the Institut National de la Santé et de la Recherche Médicale (France), the University of Nice, the Programme Hospitalier de Recherche Clinique (CHU of Nice), and charities (AFEF/Schering-Plough and AFEF/ROCHE to PG and AT). This work is part of the project “Hepatic and adipose tissue and functions in the metabolic syndrome” (HEPADIP, see <http://www.hepadip.org/>), which is supported by the European Commission as an Integrated Project under the 6th Framework Programme (Contract LSHM-CT-2005-018734). VL was successively supported by the Programme Hospitalier de Recherche Clinique (CHU of Nice) and the Association pour la Recherche sur le Cancer (France). YLMB and PG are the recipients of an Interface Grant from CHU of Nice.

COMPETING INTERESTS: None

FINANCIAL DISCLOSURE: Nothing to disclose

Most important aspect of the paper: A non invasive scoring system including metabolic syndrome, alanine aminotransferase and Cytokeratin-18 fragments was able to accurately predict definitive NASH in morbidly obese subjects.

ACKNOWLEDGMENTS:

The authors thank Dr E Floch and Newmed Publishing Services for editing the draft and Dr M Dahman, Mrs A Fafin and Dr E Mariné-Barjoan for their assistance.

Abbreviations:

ALT: alanine aminotransferase

AST: aspartate aminotransferase

AUROC: area under receiver-operating characteristic (curve)

BMI: body mass index

BP: blood pressure

CRP: C-reactive protein

γ GT: γ glutamyl transferase

HDL: high-density lipoprotein

HOMA-IR: homeostasis model assessment of insulin resistance

LDL: low-density lipoprotein

MS: metabolic syndrome

NAFLD: non-alcoholic fatty liver disease

NAS: NAFLD activity score

NASH: non-alcoholic steatohepatitis

ROC: receiver-operating characteristic

For Peer Review

TABLES

Table 1: Distribution of parameters according to NAS score in the training morbidly obese patient cohort (n=310).

NAS	n	Age (years)	Gender (M/F)	BMI (kg/m ²)	CK18 fragment levels (IU/L)	ALT (IU/L)	IDF MS (Absent/Present)
0	20	30.5 ± 9.2	0/20	43.7 ± 2.6	216.3 ± 114.6	21.0 ± 8.5	16/4
1	105	40.2 ± 11.0	8/97	44.7 ± 4.7	231.3 ± 114.6	23.7 ± 10.9	59/46
2	72	40.5 ± 10.0	10/62	44.4 ± 5.4	225.4 ± 138.3	31.8 ± 25.5	35/37
3	59	40.8 ± 11.0	11/48	44.6 ± 4.8	253.4 ± 158.9	43.3 ± 21.1	25/34
4	15	42.4 ± 8.7	5/10	45.5 ± 5.0	254.2 ± 130.6	38.6 ± 20.6	7/8
5	36	41.0 ± 10.3	9/27	45.3 ± 6.4	393.5 ± 250.4	63.0 ± 47.8	7/29
6	3	50.6 ± 4.7	0/3	41.9 ± 2.3	935.2 ± 198.2	118.7 ± 28.3	0/3
7	0	-	-	-	-	-	-
8	0	-	-	-	-	-	-

Results are expressed as means ± standard deviation, or as absolute numbers. Metabolic syndrome (MS) was defined according to the definition of the International Diabetes Federation (IDF). NAS: Non-Alcoholic Fatty Liver Disease Activity Score ; M: Male ; F: Female ; BMI: Body Mass Index; ALT: alanine amino-transferase.

Table 2: Univariate analysis of the training patient cohort (n=310) according to the severity of liver disease.

	Liver disease according to NAFLD Activity Score (NAS)		
	NAS <5 (n=271)	NAS ≥5 (n=39)	P
Age (years)	39.8 ± 10.8	41.7 ± 10.2	NS
Gender (M/F)	34/237	9/30	NS
BMI (kg/m ²)	44.6 ± 4.8	45.0 ± 6.2	NS
Waist circumference (cm)	119.7 ± 13.1	126.9 ± 15.6	0.002
ALT (IU/L)	30.7 ± 20.1	67.4 ± 48.8	<0.0000001
γGT (IU/L)	38.8 ± 34.2	73.6 ± 54.4	<0.0000001
HDL Cholesterol (mmol/L)	1.4 ± 0.3	1.3 ± 0.3	0.008
Triglyceride (mmol/L)	1.65 ± 1.16	2.6 ± 2.1	0.00002
Blood glucose level (mmol/L)	5.9 ± 2.2	7.6 ± 3.3	0.00006
C-peptide (pmol/L)	1047.5 ± 405.2	1402.9 ± 442.8	0.000006
Glycosylated hemoglobin (%)	5.9 ± 1.1	6.8 ± 1.6	0.000009
HOMA-IR	5.5 ± 5.9	9.2 ± 6.6	0.0007
Ferritin (μmol/L)	74.3 ± 77.5	142.8 ± 165.6	0.00003
CK18 fragment levels (IU/L)	234.9 ± 132.0	445.9 ± 292.5	<0.0000001
Type 2 Diabetes (%)	19.6	43.6	0.03
IDF MS (%)	47.6	82.1	0.003

Patients were classified as without or with a NAFLD Activity Score (NAS) <5 or ≥5. Quantitative results are expressed as means ± standard deviation. Metabolic syndrome (MS) was defined according to the definition of the International Diabetes Federation (IDF); M :Male ; F :Female ; NS : Not Significant; BMI: Body Mass Index; ALT: alanine amino-transferase; γGT : Gamma Glutamyl Transpeptidase ; HDL: high density lipoprotein ; HOMA-IR: homeostasis model assessment of insulin resistance.

Table 3: Multivariate analysis of the training patient cohort (n=310) according to the severity of liver disease.

	Liver disease according to NAFLD Activity Score (NAS)		
	NAS ≥ 5 (n=39) versus NAS < 5 (n=271)		
	P	OR	95%CI
ALT	0.002	1.04	1.01-1.07
γ GT	0.6	0.99	0.98-1.01
HOMA-IR	0.6	0.98	0.92-1.05
CK18 fragment levels	0.044	1.003	1.00006-1.005
Gender	0.7	0.82	0.21-3.19
IDF MS	0.005	7.3	1.8-29.4

Patients were classified as without or with a NAFLD Activity Score (NAS) < 5 or ≥ 5 . Metabolic syndrome (MS) was defined according to the definition of the International Diabetes Federation (IDF); ALT: alanine amino-transferase; γ GT: Gamma Glutamyl Transpeptidase; HOMA-IR: homeostasis model assessment of insulin resistance.

Table 4: Diagnostic accuracy of the *NiceModel* to predict NAS ≥ 5 in the training cohort of morbidly obese patients (n=310).

Cutoff value	Sensitivity	Specificity	Likelihood ratio	Positive Predictive value (prevalence 0.12)	Negative Predictive Value
0.10	0.87	0.80	4.3	0.36	0.98
0.12	0.87	0.81	4.6	0.38	0.98
0.13	0.84	0.84	5.2	0.41	0.98
0.14	0.84	0.86	5.9	0.44	0.98
0.17	0.68	0.89	6.0	0.44	0.95
0.20	0.58	0.92	6.9	0.47	0.94
0.29	0.48	0.95	10.4	0.57	0.93
0.51	0.35	0.97	14.0	0.65	0.92
0.68	0.23	0.99	26.6	0.78	0.91
0.83	0.16	0.99	38.1	0.9	0.91

Table 5: Comparative analysis between the training (n=310) and the validation (n=154) cohort of morbidly obese patients.

	Training patient cohort (n=310)	Validation patient cohort (n=154)	P
Age (years)	40.0±10.7	39.3±10.8	NS
Gender (M/F)	43/267	19/135	NS
BMI (kg/m ²)	44.6±5.0	44.4±5.7	NS
ALT (IU/L)	35.3±28.1	34.4±26.3	NS
CK18 fragment levels (IU/L)	259.2±172.0	242.5±178.0	NS
IDF MS	52% (161/310)	52% (80/154)	NS

Metabolic syndrome (MS) was defined according to the definition of the International Diabetes Federation (IDF);

NS : Not Significant; M :Male ; F :Female ; BMI: Body Mass Index; ALT: alanine amino-transferase.

Table 6: AUROC curves of published scoring systems applied in the entire cohort (n=464) to diagnose $NAS \geq 5$.

Scoring system	AUROC curve in the original study	AUROC curve in the entire cohort (n=464)
Dixon et al. (HAIR) ¹⁷	0.9	0.77
Gholam et al. ¹⁸	0.82	0.79
Palekar et al. ¹⁵	0.76	0.44

AUROC: area under receiver-operating characteristic. Among published scoring models only those with items available in the cohort were studied.

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure Legends

Figure 1: *NiceModel* receiver-operating characteristic (ROC) curves for the diagnosis of definitive NASH (NAS ≥ 5) in morbidly obese patients.

NiceModel ROC curves are shown for the training patient cohort (n=310) and validation patient cohort (n=154).

Figure 2: Distribution of values for the *NiceModel* (based on ALT, CK18 fragment levels and the presence of IDF metabolic syndrome) according to the severity of liver histology in the training cohort (n=310).

(A) Distribution according to NAS values: simple steatosis (NAS ≤ 2), borderline Group ($3 \leq \text{NAS} \leq 4$), and definitive NASH (NAS ≥ 5). (B) Distribution according to NAS values: NAS ≥ 5 or NAS < 5 .

For Peer Review

STARD checklist for reporting of studies of diagnostic accuracy
(version January 2003)

Section and Topic	Item #		On page #
TITLE/ABSTRACT/ KEYWORDS	1	Identify the article as a study of diagnostic accuracy (recommend MeSH heading 'sensitivity and specificity').	Page 1
INTRODUCTION	2	State the research questions or study aims, such as estimating diagnostic accuracy or comparing accuracy between tests or across participant groups.	Page 4
METHODS			
<i>Participants</i>	3	The study population: The inclusion and exclusion criteria, setting and locations where data were collected.	Page 5
	4	Participant recruitment: Was recruitment based on presenting symptoms, results from previous tests, or the fact that the participants had received the index tests or the reference standard?	Recruitment was based on systematic enrolment during bariatric surgery
	5	Participant sampling: Was the study population a consecutive series of participants defined by the selection criteria in item 3 and 4? If not, specify how participants were further selected.	All consecutive morbidly obese patients were analysed. The cohort was arbitrarily split in a training and a validation cohort.
	6	Data collection: Was data collection planned before the index test and reference standard were performed (prospective study) or after (retrospective study)?	It is a prospective study.
<i>Test methods</i>	7	The reference standard and its rationale.	Systematic liver biopsy which is the Gold Standard for NASH
	8	Technical specifications of material and methods involved including how and when measurements were taken, and/or cite references for index tests and reference standard.	Yes, page 5 and 6
	9	Definition of and rationale for the units, cut-offs and/or categories of the results of the index tests and the reference standard.	"Definitive NASH" (NALFD Activity Score ≥ 5) was retained according to Kleiner's classification.
	10	The number, training and expertise of the persons executing and reading the index tests and the reference standard.	All liver biopsies were read by a specialized pathologist (MCSP). Kleiner's classification was secondly determined by MCSP and SP.
	11	Whether or not the readers of the index tests and reference standard were blind (masked) to the results of the other test and describe any other clinical information available to the readers.	Yes, the readers of the liver biopsy were blind to the results of the proposed model.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

<i>Statistical methods</i>	12	Methods for calculating or comparing measures of diagnostic accuracy, and the statistical methods used to quantify uncertainty (e.g. 95% confidence intervals).	Comparisons were done using the Chi ² test or Fischer's exact tests for nominal data and by two-sample <i>t</i> tests for continuous data. Multivariate analyses were performed using binary logistic regression with estimation of odds ratios (OR) and 95% confidence intervals (95%CI). Only variables with $p < 0.05$ in multivariate analyses were retained for the final model. The diagnostic performance of this model was determined by constructing a receiver-operating characteristic (ROC) curve and calculating the area under ROC (AUROC) curve for predicting patients with NAS ≥ 5 .
	13	Methods for calculating test reproducibility, if done.	Not done.
RESULTS			
<i>Participants</i>	14	When study was performed, including beginning and end dates of recruitment.	Page 5
	15	Clinical and demographic characteristics of the study population (at least information on age, gender, spectrum of presenting symptoms).	Table 1 and table 5
	16	The number of participants satisfying the criteria for inclusion who did or did not undergo the index tests and/or the reference standard; describe why participants failed to undergo either test (a flow diagram is strongly recommended).	All the patients satisfying the criteria for inclusion were enrolled in the study.
<i>Test results</i>	17	Time-interval between the index tests and the reference standard, and any treatment administered in between.	Clinical and biological data were collected few days before the bariatric surgery after overnight fasting. Liver biopsy was done during surgery.
	18	Distribution of severity of disease (define criteria) in those with the target condition; other diagnoses in participants without the target condition.	Among morbidly obese patients enrolled in the training cohort 12.6% had a "definitive NASH" (NALFD Activity Score ≥ 5)
	19	A cross tabulation of the results of the index tests (including indeterminate and missing results) by the results of the reference standard; for continuous results, the distribution of the test results by the results of the reference standard.	The distribution of the test results by the results of liver biopsy is presented in Figure 2.
	20	Any adverse events from performing the index tests or the reference standard.	No adverse events occurred.
<i>Estimates</i>	21	Estimates of diagnostic accuracy and measures of statistical uncertainty (e.g. 95% confidence intervals).	AUROC curves of the scoring system were 0.88 and 0.83 in the training and in the validation group respectively.
	22	How indeterminate results, missing data and outliers of the index tests were handled.	A borderline group is determined in the Kleiner's classification. Diagnostic accuracy is given in the table 4.
	23	Estimates of variability of diagnostic accuracy between subgroups of participants, readers or centers, if done.	AUROC curves of the scoring system were 0.88 and 0.83 in the training and in the validation group respectively.
	24	Estimates of test reproducibility, if done.	Not done

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

DISCUSSION	25	Discuss the clinical applicability of the study findings.	ALT level and Metabolic syndrome determination are done routinely. Blood levels of apoptotic caspase-3 generated CK18 fragment levels were measured using a commercial kit. External validation in non morbidly obese patients will be necessary. Pages 10 & 11.
------------	----	---	--

For Peer Review

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1: NiceModel receiver-operating characteristic (ROC) curves for the diagnosis of definitive NASH (NAS ≥ 5) in morbidly obese patients. NiceModel ROC curves are shown for the training patient cohort (n=310) and validation patient cohort (n=154).

322x226mm (72 x 72 DPI)

view




Figure 2: Distribution of values for the NiceModel (based on ALT, CK18 fragment levels and the presence of IDF metabolic syndrome) according to the severity of liver histology in the training cohort (n=310). (A) Distribution according to NAS values: simple steatosis (NAS ≤ 2), borderline Group (3 ≤ NAS ≤ 4), and definitive NASH (NAS ≥ 5). (B) Distribution according to NAS values: NAS ≥ 5 or NAS < 5.

230x324mm (96 x 96 DPI)